Published July 1, 2019 | Version v1
Journal article Metadata-only

Safety and efficacy of 125I brachytherapy for bilateral lung recurrences from hepatocellular carcinoma after resection or ablation

Creators

  • 1. Sun Yat-sen University, Department of Radiology, The Third Affiliated Hospital (China)
  • 2. Guangdong Second Provincial General Hospital, Guangdong Provincial Emergency Hospital, Department of Radiology (China)
  • 3. Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine (China)

Description

Purpose

To evaluate the safety and efficacy of 125I brachytherapy to treat bilateral lung recurrences from hepatocellular carcinoma (HCC) after resection or ablation.

Materials and methods

We retrospectively recruited 95 patients with bilateral lung recurrences from hepatocellular carcinoma (HCC) after resection or ablation who had received 3–6-month sorafenib with or without stereotactic body radiotherapy (SBRT), from October 2011 to January 2015; patients were then randomly divided into two groups, 44 patients received computed tomography (CT)-guided 125I brachytherapy (group A), and 51 patients were treated with supportive and symptomatic treatments (group B).

Results

The median survival time was 19 months (range of 3–36 months). The local response rate (LRR) at 3, 6, 12, 18, 24, 30 and 36 months in group A was 81.8%, 65.9%, 59.1%, 45.0%, 38.6%, 22.7%, 11.4%, respectively, and 64.7%, 47.1%, 33.3%, 25.4%, 15.7%, 11.7%, 7.8%, respectively, in group B (P < 0.05). The mean progression-free survival time (PFST) and overall survival (OS) of group A were significantly longer than those of group B. Alpha fetoprotein (AFP) and tumor size were independent factors that affected the PFST and OS, normal AFP levels and less than 1-cm tumor diameter had better PFST and OS (P < 0.05). No massive bleeding or serious complications occurred.

Conclusion

CT-guided 125I brachytherapy is safe and effective for the treatment of bilateral lung recurrences from HCC after resection or ablation.

Additional details

Identifiers

DOI
10.1007/s00432-019-02943-x;

Publishing Information

Journal Title
Journal of Cancer Research and Clinical Oncology
Journal Volume
145
Journal Issue
7
Journal Page Range
p. 1907-1916
ISSN
0171-5216
CODEN
JCROD7

INIS

Country of Publication
Germany
Country of Input or Organization
International Atomic Energy Agency (IAEA)
INIS RN
54072646
Subject category
S62: RADIOLOGY AND NUCLEAR MEDICINE;
Descriptors DEI
ABLATION; BRACHYTHERAPY; COMPUTERIZED TOMOGRAPHY; HEPATOMAS; IODINE 125; LUNGS; PATIENTS; SURVIVAL TIME
Descriptors DEC
BETA DECAY RADIOISOTOPES; BODY; CARCINOMAS; DAYS LIVING RADIOISOTOPES; DIAGNOSTIC TECHNIQUES; DISEASES; ELECTRON CAPTURE RADIOISOTOPES; INTERMEDIATE MASS NUCLEI; INTERNAL CONVERSION RADIOISOTOPES; IODINE ISOTOPES; ISOTOPES; MEDICINE; NEOPLASMS; NUCLEAR MEDICINE; NUCLEI; ODD-EVEN NUCLEI; ORGANS; RADIOISOTOPES; RADIOLOGY; RADIOTHERAPY; RESPIRATORY SYSTEM; THERAPY; TOMOGRAPHY

Optional Information

Copyright
Copyright (c) 2019 Springer-Verlag GmbH Germany, part of Springer Nature